Indoco Remedies has sets up R&D facility to boost its Contract Research and Manufacturing business.

Indoco Remedies has set up a new R&D centre at Navi Mumbai at a cost of Rs. 225 million. According to Ms . Aditi  Kare Panandikar, Director Business Development Indoco aims to transform completely as an integrated player in CRAMS market.

The research activities at the R&D centre includes synthesis of APIs, process improvement and development of non-infringing processes for APIs & intermediates, Formulations development, Analytical studies & Regulatory affairs. The facility would be aimed to work for firms from the European countries and US market. Unique feature of the R&D centre is the Kilolab, which is versatile to perform a wide variety of reactions and complete multistage intermediate and API processes for preclinical phase to Phase III clinical studies, and will in turn amplify Indoco’s contract development and manufacturing services to the rest of the world.

Indoco views its R&D capabilities as a vital component of its business strategy that will provide the company Long-term Competitive advantage. The company intends to take up NDDS research and expects to commercialize the first NDDS product in calendar 2008, It in process of setting up a separate R&D team for the same.

Indoco now has 5 facilities for formulation i.e. Goa Plant I {Oral Solids, Creams & Liquid Dosage Plant: Approved by MHRA-UK & Darmstadt Germany} Goa Plant II {Sterile Facility for Ophthalmic & Injectables: Approved by USFDA} Baddi {WHO: GMP}, Aurangabad & Tarapur facilities for non regulated market. Kilolab is backed two commercial manufacturing facilities at Patalganga as per USFDA standards & at Rabale as per WHO: GMP standards for API, scale up facility.